BACKGROUND: Impulsivity and dopamine dysregulation syndrome are frequent complications of treatment in Parkinson's disease (PD). METHODS: We assessed the effect of jejunal levodopa infusion (JLI) on behavioral symptoms in 8 PD patients with motor complications and severe impulsivity and dopamine dysregulation syndrome (DDS), which had not be controlled before by adjusting oral medications. The infusion was delivered during 15 hours (daily dose 1007.2 ± 302.5 mg) and stopped at night time. Patients were reassessed after 25 ± 9 weeks of treatment with a stable dose of jejunal l-dopa. RESULTS: Off periods and dyskinesias decreased by 27% and 20,7% respectively, compared to baseline. DDS and all types of impulse control disorders (ICDs) improved in all patients, with nearly complete symptom resolution. Punding improved in all 5 patients but disappeared completely in only 1. CONCLUSIONS: Our experience suggests that l-dopa infusion has a positive effect on both motor complications and behavioral disorders. This treatment approach deserves further controlled studies.
BACKGROUND:Impulsivity and dopaminedysregulation syndrome are frequent complications of treatment in Parkinson's disease (PD). METHODS: We assessed the effect of jejunal levodopa infusion (JLI) on behavioral symptoms in 8 PDpatients with motor complications and severe impulsivity and dopaminedysregulation syndrome (DDS), which had not be controlled before by adjusting oral medications. The infusion was delivered during 15 hours (daily dose 1007.2 ± 302.5 mg) and stopped at night time. Patients were reassessed after 25 ± 9 weeks of treatment with a stable dose of jejunal l-dopa. RESULTS: Off periods and dyskinesias decreased by 27% and 20,7% respectively, compared to baseline. DDS and all types of impulse control disorders (ICDs) improved in all patients, with nearly complete symptom resolution. Punding improved in all 5 patients but disappeared completely in only 1. CONCLUSIONS: Our experience suggests that l-dopa infusion has a positive effect on both motor complications and behavioral disorders. This treatment approach deserves further controlled studies.
Authors: Michael Samuel; Maria Rodriguez-Oroz; Angelo Antonini; Jonathan M Brotchie; Kallol Ray Chaudhuri; Richard G Brown; Wendy R Galpern; Melissa J Nirenberg; Michael S Okun; Anthony E Lang Journal: Mov Disord Date: 2015-01-21 Impact factor: 10.338
Authors: Maria Jose Catalan; Jose Antonio Molina-Arjona; Pablo Mir; Esther Cubo; Jose Matias Arbelo; Pablo Martinez-Martin Journal: J Neurol Date: 2018-03-20 Impact factor: 4.849
Authors: Kala Venkiteswaran; Danielle N Alexander; Matthew D Puhl; Anand Rao; Amanda L Piquet; Jennifer E Nyland; Megha P Subramanian; Puja Iyer; Matthew M Boisvert; Erin Handly; Thyagarajan Subramanian; Patricia Sue Grigson Journal: Brain Res Bull Date: 2015-11-10 Impact factor: 4.077